From management perspective it makes sense that AVH has not not...

From management perspective it makes sense that AVH has not not been calibrated for profitability yet, as they are still focused on penetrating their large market opportunities… anyone who’s asking to stop spending into trials for Vitiligo and tissue reconstruction perhaps should not be invested into companies like AVH

whether management could have navigated covid better or not … who knows - perhaps this is where alot of deserved criticism… but hey im sure it creates enough motivation for the management to see their options under water at the moment

anyways looking at fundamentals and beyond short term market sentiments, there are plenty of major growth catalyst in the not too distant future… could SP go lower than $2 of cause it could but I doubt it would stay their when/if we hear for example about outpatient launch or vitiligo / trauma positive trail data…